{
    "organizations": [],
    "uuid": "35f25ad77196e72813a14bdee7b510a514e78344",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-says-receives-fda-approva/brief-novartis-says-receives-fda-approval-of-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma-idUSASO00042B",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis Says Receives FDA Approval Of Tafinlar + Mekinist For Adjuvant Treatment Of Braf V600-Mutant Melanoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Novartis AG:\n* RECEIVES FDA APPROVAL OF TAFINLAR + MEKINIST FOR ADJUVANT TREATMENT OF BRAF V600-MUTANT MELANOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T04:15:00.000+03:00",
    "crawled": "2018-05-01T00:23:24.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novartis",
        "ag",
        "receives",
        "fda",
        "approval",
        "tafinlar",
        "mekinist",
        "adjuvant",
        "treatment",
        "braf",
        "melanoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}